Report #2865534

Received Oct 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Mar 2, 2025
Onset: Mar 2, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	55TH4	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

first being administered in 11-AUG-2023 and second was given March 2nd, 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 53-year-old female patient who received Herpes zoster (Shingrix) (batch number 55TH4, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on 11-AUG-2023 Batch no.: 3777F Expiry date: 30-MAY-2024). On 02-MAR-2025, the patient received the 2nd dose of Shingrix. On 02-MAR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: first being administered in 11-AUG-2023 and second was given March 2nd, 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 19-SEP-2025 A pharmacist called in to request data about the stability of Shingrix.